Additional file 2 of Use of almitrine in spontaneously breathing patients with COVID-19 treated with high-flow nasal cannula oxygen therapy and with persistent hypoxemia

Saccheri, Clément; Morand, Lucas; Juston, Marie; Doyen, Denis; Hyvernat, Hervé; Lombardi, Romain; Devanlay, Raphaël; Panicucci, Émilie; Dellamonica, Jean; Jozwiak, Mathieu

doi:10.6084/m9.figshare.22602676.v1

12931_2022_2308_MOESM2_ESM.docx (350.52 kB)

Additional file 2 of Use of almitrine in spontaneously breathing patients with COVID-19 treated with high-flow nasal cannula oxygen therapy and with persistent hypoxemia

journal contribution

posted on 2023-04-13, 10:13 authored by Clément Saccheri, Lucas Morand, Marie Juston, Denis Doyen, Hervé Hyvernat, Romain Lombardi, Raphaël Devanlay, Émilie Panicucci, Jean Dellamonica, Mathieu Jozwiak

Additional file 2: Transthoracic echocardiographic measurements. Figure S1. Study protocol. HFNO: high-flow nasal cannula oxygen therapy, FiO2: inspired oxygen fraction; PaO2: partial arterial pressure of oxygen. Figure S2. Receiver operating characteristics curve for the ability of the ROX index to predict the response to almitrine (n = 62). AUC = area under the curve, expressed as mean [95% confidence interval].